Atherosclerosis and Hyperlipidemia

ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s

Yoshiyasu Minami , Daisuke Kinoshita , Yusuke Muramatsu , et al

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46m 28s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s

Media

ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
ESC 2017: The GLAGOV Trial

Stephen J Nicholls,

Watch time: 4m 11s
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

Watch time: 3m 31s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s

Articles

Lipoprotein(a) and Cardiovascular Disease

Yoshiyasu Minami

,

Daisuke Kinoshita

,

Yusuke Muramatsu

,

Takako Nagata

,

Junya Ako

,

Published:

13 May 2022

Citation:

Journal of Asian Pacific Society of Cardiology 2022;1:e11.

DOI:

https://doi.org/10.15420/japsc.2021.31
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2587
  • Downloads: Downloads 92
  • Citations: 1